# Open Orphan contract renewal with top-3 global pharmaceutical client

- Link: https://www.directorstalkinterviews.com/open-orphan-contract-renewal-with-top-3-global-pharmaceutical-client/412949835
- Published: 2020-12-22T07:06:56+00:00
- Author: Giles

**Open Orphan plc** ([LON:ORPH](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l)),
a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine
and antiviral testing using human challenge clinical trials, has announced a contract
renewal extending its consultancy services with a major top-3 global pharmaceutical
client to December 2021.

Through the Venn Life Sciences team in the Breda office in the Netherlands, Open
Orphan provides independent, up-to-date and hands-on Chemistry, Manufacturing & 
Control consultancy services to a leading global pharmaceutical client and has done
since 2012. Venn’s CMC consultancy team provide essential support for two of this
client’s vaccine development programmes and these successful collaborations have
been extended until December 2021.

Venn’s CMC consultancy services focus on the strategic and technical aspects of 
pharmaceutical development and

support the management of pharmaceutical development programmes covering small molecules
and biologicals from chemical or cell line development up to submission of marketing
authorisation application.

> **Cathal Friel, Executive Chairman of Open Orphan, said: **“This contract renewal
> underpins our confidence in delivering against ambitious growth targets for 2021
> and securing strong revenue visibility moving forward. Our strengths lie in the
> established relationships we have with our pharmaceutical partners and we expect
> to continue to extend these relationships as well as focussing on converting the
> existing pipeline of new business opportunities we have before us.
> “Market consensus forecast a significant increase in revenues in 2021. As we remain
> on target to be operationally profitable in the final quarter of this year, we
> also expect to see a significant impact on earnings next year from this revenue
> growth.”

Share on:
